Clinical Trial Detail

NCT ID NCT02186301
Title TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Clovis Oncology, Inc.
Indications

non-small cell lung carcinoma

Therapies

Rociletinib

Erlotinib

Age Groups: adult

Additional content available in CKB BOOST